The Calmare® device is a U.S. FDA 510(k)-cleared and European CE mark-certified pain therapy medical device for the non-invasive treatment of chronic neuropathic and oncologic pain. Treatment using the Calmare device avoids the harmful, potentially fatal, adverse side effects and addictive properties linked to narcotic pain killers.
The Calmare device has been used to successfully treat over 4,000 patients worldwide, where it has been shown to be effective in treating neuropathic and oncologic pain. Conditions treated include:
Chemotherapy-induced peripheral neuropathy (CIPN)
Phantom limb syndrome
Sciatica
Post-surgical neuropathic pain
Low back pain
Neck pain
Reflex sympathetic dystrophy
Postherpetic neuralgia (PHN)
The device is currently being used in the US at these key teaching hospitals:
Virginia Commonwealth University's Massey Cancer Center
Paul Carbone Cancer Center at University of Wisconsin-Madison
The device, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. The device creates and sends a no-pain signal which becomes the dominant signal received by the brain, thus overriding the pain signal and providing relief for the patient.
In honor of the technology's Italian inventors, CTI chose to call this medical device "Calmare". Translated from Italian, "calmare" means "to soothe or ease." Treatment utilizing the Calmare device eases the suffering that patients endure from debilitating pain.
AI
